ZNF22

Across TCGA pan-cancer cohorts, ZNF22 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZNF22 data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher ZNF22 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF22 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, DLBC, and ESCA are the cancer types where ZNF22 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.168	0.675	.021	18	view →
DLBC	OS	Median	All	0.054	0.842	<.001	12	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
UCEC	DFS	Median	All	0.964	0.627	.021	6	view →
LUAD	DFS	Median	All	0.213	0.676	.012	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZNF22–LUSC (OS)

Open the LUSC breakdown →